2012

21/05/12
Stallergenes remains committed to the recognition of innovative pharmaceutical companies and has joined G5 Health

04/05/12
Stallergenes announces positive clinical results for its house dust mites immunotherapy tablet

Results of a clinical study (VO67.10) of the house dust mites sublingual immunotherapy tablet, conducted in an Environmental Exposure Chamber (EEC).

02/04/12
Stallergenes has identified two candidate biomarkers of early efficacy of allergen immunotherapy

21/03/12
Stallergenes continues its strategic international expansion with the successful registration in Canada of Oralair™ tablet for grass pollen

19/03/12
2011 Annual Results

Strong profitability supporting international expansion

• Sales up 9%

• Net profit up 20%

• Net cash of € 70 Million

12/01/12
2011 Sales up

2011 sales up 9%

Market share gains